Parliamentary Search

Written question asked by Lord Moonie (Non-affiliated) on Thursday, 21 January 2021, in the House of Lords. It was due for an answer on Thursday, 4 February 2021. It was answered by Lord Callanan (Conservative) on Thursday, 4 February 2021 on behalf of the Department for Business, Energy and Industrial Strategy.

Coronavirus: Vaccination

Question

To ask Her Majesty's Government what assessment they have made of the progress of trials of each of the COVID-19 vaccines for which they have placed orders; and when they expect to take delivery of the first doses of those vaccines.

Original answer

The UK Government has secured early access to 367 million vaccine doses through agreements with seven separate vaccine developers. The Government is working closely with vaccine developers to monitor progress of clinical trials.

  • The Pfizer/BioNTech vaccine was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and this vaccine is already being deployed in the UK.
  • The Oxford/AstraZeneca vaccine was approved by the MHRA and this vaccine is already being deployed in the UK.
  • The Moderna vaccine was approved by the MHRA. Supplies of this vaccine will begin to be delivered to the UK from the spring once Moderna expands its production capability.
  • The Janssen vaccine is currently in phase 3 clinical trials. If clinical trials prove the vaccine to be safe and effective, supplies of the vaccine could start to be delivered to the UK in the second half of 2021.
  • The Novavax vaccine is currently in phase 3 clinical trials. If clinical trials prove the vaccine to be safe and effective, supplies of the vaccine could start to be delivered to the UK in the second half of 2021.
  • The GlaxoSmithKline/SanofiPasteur vaccine is currently in phase 1/2 clinical trials. Deliveries of this vaccine are being discussed with the developer and dependent upon the vaccine being found to be safe and effective.
  • The Valneva vaccine is currently in phase 1/2 clinical trials. If clinical trials prove the vaccine to be safe and effective, supplies of the vaccine could be made available to the UK by the end of 2021.

The answer was corrected by Lord Callanan (Conservative)

on Thursday, 4 February 2021 on behalf of the Department for Business, Energy and Industrial Strategy.

Corrected answer

The UK Government has secured early access to 367 407 million vaccine doses through agreements with seven separate vaccine developers. The Government is working closely with vaccine developers to monitor progress of clinical trials.

  • The Pfizer/BioNTech vaccine was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and this vaccine is already being deployed in the UK.
  • The Oxford/AstraZeneca vaccine was approved by the MHRA and this vaccine is already being deployed in the UK.
  • The Moderna vaccine was approved by the MHRA. Supplies of this vaccine will begin to be delivered to the UK from the spring once Moderna expands its production capability.
  • The Janssen vaccine is currently in phase 3 clinical trials. If clinical trials prove the vaccine to be safe and effective, supplies of the vaccine could start to be delivered to the UK in the second half of 2021.
  • The Novavax vaccine is currently in phase 3 clinical trials. If clinical trials prove the vaccine to be safe and effective, supplies of the vaccine could start to be delivered to the UK in the second half of 2021.
  • The GlaxoSmithKline/SanofiPasteur vaccine is currently in phase 1/2 clinical trials. Deliveries of this vaccine are being discussed with the developer and dependent upon the vaccine being found to be safe and effective.
  • The Valneva vaccine is currently in phase 1/2 clinical trials. If clinical trials prove the vaccine to be safe and effective, supplies of the vaccine could be made available to the UK by the end of 2021.

Secondary information

Type
Written question
Reference
HL12442
Session
2019-21
Related items
Coronavirus: Vaccination
Thursday, 29 April 2021
Written questions
House of Lords
Subjects
Vaccination Clinical trials Coronavirus
Link
View this Written question on www.parliament.uk